Insider Sale: CFO Jane Henderson Sells 6,000 Shares of Apogee Therapeutics Inc (APGE)
In This Article:
On August 23, 2024, Jane Henderson, the Chief Financial Officer of Apogee Therapeutics Inc (NASDAQ:APGE), sold 6,000 shares of the company at a price of $48.26 per share. The transaction was documented in an SEC Filing. Following this sale, the insider now owns 200,871 shares of Apogee Therapeutics Inc.
Apogee Therapeutics Inc is engaged in the development and commercialization of various therapies aimed at treating diseases with significant unmet medical needs. The company's focus includes a pipeline of novel therapeutic products.
Over the past year, the insider transaction history at Apogee Therapeutics Inc shows a total of 5 insider sells and no insider buys. The insider, Jane Henderson, has sold a total of 6,000 shares and has not purchased any shares within this timeframe.
The shares of Apogee Therapeutics Inc were trading at $48.26 on the day of the transaction, giving the company a market cap of approximately $2.74 billion. This valuation reflects the company's current price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow.
The following insider trend image provides a visual representation of the recent insider transactions at Apogee Therapeutics Inc:
For more detailed valuation metrics, such as the GF Value of Apogee Therapeutics Inc, investors and stakeholders are encouraged to visit the provided links.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.